Source:http://linkedlifedata.com/resource/pubmed/id/11275989
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2001-3-29
|
pubmed:abstractText |
The purpose of this study was to determine, as we did for paclitaxel, the cytotoxic and radiosensitizing potential of docetaxel in human head and neck cancer cells (ZMK-1), and in cervical squamous cell carcinoma cells (CaSki). ZMK-1 cells were incubated with docetaxel for 3, 9 or 24 hr before irradiation and 24 hr after irradiation. CaSki cells were incubated with docetaxel 24 hr before and after irradiation. For ZMK-1 cells, the docetaxel concentrations (0.7, 0.7 and 0.35 nM) were determined to obtain approximately equivalent cell survival at the different incubation times (3, 9 and 24 hr, respectively). For CaSki cells, the necessary concentration of docetaxel was 0.07 nM. Radiation doses were given from 0 to 7 Gy. Cell survival was measured by a standard clonogenic assay after a 9-day incubation. Flow cytometry was used to measure the capacity of docetaxel to accumulate cells in the G2/M phase of the cell cycle. We observed a weak accumulation of cells in the G2/M phase for the ZMK-1 cells and a pronounced accumulation for CaSki cells. For docetaxel incubation before irradiation, the isoeffect enhancement ratios for ZMK-1 cells determined at the 37% survival level were 1.18, 2.01, and 2.40 for pre-incubation at 3, 9 and 24 hr, respectively; for CaSki cells the ratio was 1.44. For a docetaxel incubation of 24 hr after irradiation, the isoeffect enhancement ratios determined at the 37% survival level were 1.54 and 1.17 for the ZMK-1, and CaSki cells, respectively. A radiosensitizing effect of docetaxel could be demonstrated unambiguously in the two cell lines used. In contrast to our previously published results with paclitaxel, docetaxel seems to be a better radiosensitizer than paclitaxel.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2001 Wiley-Liss, Inc.
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
91
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
840-5
|
pubmed:dateRevised |
2007-7-24
|
pubmed:meshHeading |
pubmed-meshheading:11275989-Carcinoma, Squamous Cell,
pubmed-meshheading:11275989-Cell Cycle,
pubmed-meshheading:11275989-Cell Survival,
pubmed-meshheading:11275989-Combined Modality Therapy,
pubmed-meshheading:11275989-Dose-Response Relationship, Drug,
pubmed-meshheading:11275989-Female,
pubmed-meshheading:11275989-Flow Cytometry,
pubmed-meshheading:11275989-Head and Neck Neoplasms,
pubmed-meshheading:11275989-Humans,
pubmed-meshheading:11275989-Paclitaxel,
pubmed-meshheading:11275989-Radiation Tolerance,
pubmed-meshheading:11275989-Radiation-Sensitizing Agents,
pubmed-meshheading:11275989-Radiotherapy,
pubmed-meshheading:11275989-Taxoids,
pubmed-meshheading:11275989-Time Factors,
pubmed-meshheading:11275989-Tumor Cells, Cultured,
pubmed-meshheading:11275989-Uterine Cervical Neoplasms
|
pubmed:year |
2001
|
pubmed:articleTitle |
Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki ).
|
pubmed:affiliation |
Department of Radiotherapy and Radiation Oncology, University of Göttingen, Robert-Koch-Str. 40, D 37075 Göttingen, Germany. opradie@gwdg.de
|
pubmed:publicationType |
Journal Article,
Comparative Study
|